Roche, Areva deal

Macrocyclics Inc., a subsidiary of Areva's Areva Med LLC (Bethesda, Md.) subsidiary, and Roche amended a 2012 deal under which the partners are creating an alpha radio-immunotherapy platform to treat cancer by assessing the efficacy of combining Roche-engineered antibodies with Areva's radionuclide, Lead-212. Under the amendment, Macrocyclics will design novel chelating agents for undisclosed Roche oncology applications. Macrocyclics said the new project will utilize Lead-212, as well as novel chelate architecture for radio-immunotherapy. The companies declined to disclose details. ...